Document Detail


House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
MedLine Citation:
PMID:  19696440     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Sublingual allergen-specific immunotherapy is gaining popularity for treatment of allergic diseases, but underlying immunological mechanisms are unresolved. OBJECTIVES: To perform detailed immunological investigation of sublingual house dust mite (HDM) immunotherapy. METHODS: A 12-month randomized double-blind placebo-controlled study of sublingual HDM immunotherapy in 30 HDM-allergic subjects was performed, with 1-year open extension in 9 patients on active treatment. HDM-stimulated blood mononuclear cells were analyzed for proliferation, cytokines, and regulatory T cells (Tregs) by flow cytometry and ELISA. Effects of blocking transforming growth factor (TGF)-beta and IL-10 on proliferation were determined. Treg suppressor function and allergen-specific antibody levels were measured. Clinical efficacy was assessed by symptom, medication, and Juniper quality-of-life scores. MEASUREMENTS AND MAIN RESULTS: Allergen-induced CD4(+) T-cell division and IL-5 production were significantly decreased after 6- and 12-months' active treatment but not placebo. sTGF-betaRII blocked immunotherapy-induced suppression of allergen-specific T-cell proliferation, maximal at 6 months. Decreased allergen-specific CD4(+) T-cell proliferation and increased IL-10 secretion and serum Der p 2-specific IgG(4) were maximal at 24 months' active treatment. Treg (CD4(+)CD25(+)CD127(lo)/Foxp3(+)) function was demonstrated by suppression of allergen-specific effector T-cell (CD4(+)CD25(-)CD127(hi)) proliferation and cytokine production. Clinical efficacy of immunotherapy was supported by significantly decreased rhinitis symptom score, total asthma score, and Juniper quality-of-life score. CONCLUSIONS: This study establishes the novel finding that TGF-beta mediates the immunological suppression seen early in clinically effective sublingual HDM immunotherapy in addition to an increase in Tregs with suppressor function. Clinical trial registered with www.clinicaltrials.gov (NCT00250263).
Authors:
Robyn E O'Hehir; Leanne M Gardner; Maria P de Leon; Belinda J Hales; Mark Biondo; Jo A Douglass; Jennifer M Rolland; Alessandra Sandrini
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-08-20
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  180     ISSN:  1535-4970     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-09     Completed Date:  2009-11-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  936-47     Citation Subset:  AIM; IM    
Affiliation:
Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia. robyn.ohehir@med.monash.edu.au
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00250263
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Sublingual
Adolescent
Adult
Aged
Allergens / administration & dosage
Animals
Asthma / therapy
Double-Blind Method
Female
Humans
Immunotherapy / methods*
Interleukin-5 / biosynthesis
Male
Middle Aged
Pyroglyphidae / immunology*
Respiratory Hypersensitivity / therapy*
Rhinitis, Allergic, Perennial / therapy
T-Lymphocytes, Regulatory / immunology*
Transforming Growth Factor beta / physiology*
Chemical
Reg. No./Substance:
0/Allergens; 0/Interleukin-5; 0/Transforming Growth Factor beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Demonstrated and inferred metabolism associated with cytosolic lipid droplets.
Next Document:  Long-term Outcomes in Mild/Moderate COPD in the European Community Respiratory Health Survey.